Electrophysiologic changes after intravitreal ranibizumab injection for the treatment of choroidal neovascular membrane (CNVM) by Bhurayanontachai, Patama et al.
© 2011 Bhurayanontachai et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
 Clinical Ophthalmology 2011:5 567–572
 Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
567
OriginAL reseArCh
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/OPTH.S19485
electrophysiologic changes after intravitreal 
ranibizumab injection for the treatment  
of choroidal neovascular membrane (CnVM)
Patama Bhurayanontachai
Mansing ratanasukon
Pichai Jirarattanasopa
retina Unit, Department of 
Ophthalmology, Faculty of Medicine, 
Prince of songkla University, hat Yai, 
songkhla, Thailand
Correspondence: Patama Bhurayanontachai 
retina Unit, Department of 
Ophthalmology, Faculty of Medicine, 
Prince of songkla University,  
hat Yai, songkhla, 90110, Thailand 
Tel +66 74 451380 
Fax +66 74 429619 
email tpatama@hotmail.com
Purpose: To determine the pattern of electroretinographic change after an intravitreal   ranibizumab 
(Lucentis®) injection for the treatment of choroidal neovascular membrane (CNVM).
Patients and methods: A prospective interventional case series of patients treated by 
intravitreal ranibizumab injection. Best corrected visual acuity, optical coherence   tomography 
(OCT), and multifocal electroretinography (mfERG) were assessed prior to treatment, and 
2 weeks, 1 and 3 months after treatment. Primary outcome was the functional change in 
  amplitude and implicit time by mfERG and secondary outcome was the structural change in 
macular thickness by optical coherence tomography (OCT).
Results: Twenty-six eyes from 25 consecutive patients were enrolled. At 3 months after 
  treatment, the mean visual acuity (VA) improved from 1.06 to 0.84 logMAR (P = 0.034) and the 
mean macular thickness decreased from 389.7 to 264.4 microns (P = 0.003). The mean implicit 
time of the central zone showed an improvement at 3 months after treatment when compared with 
the response at baseline (P = 0.024) and at 1 month (P = 0.013) but the mean amplitude showed 
no significant change. In subgroup analysis, the eyes with initial visual acuity (VA) $ 20/200 
had a significant improvement in mean implicit time of the peripheral zone at 2 weeks after 
treatment (P = 0.028). The OCT revealed a significant decrease (P , 0.003) in macular thickness 
at 1 and 3 months postoperatively.
Conclusion: The mean implicit time of the central zone improved significantly at 3 months after 
treatment, whereas the mean amplitude showed no significant change. The macular thickness 
decreased significantly after the treatment, while VA improved to a lesser extent.
Keywords: choroidal neovascular membrane (CNVM), intravitreal injection, multifocal 
  electroretinography (mfERG), optical coherence tomography (OCT), ranibizumab
Introduction
Choroidal neovascular membrane (CNVM) is an abnormal vascular proliferation 
from beneath the retina and is related to many different underlying retinal conditions, 
especially age-related macular degeneration. Over the past few years, the introduction 
of anti-vascular endothelial growth factor (anti-VEGF) drugs has changed the way 
CNVM is treated. Ranibizumab is one of the novel anti-VEGF drugs that has been 
proved to be efficient and safe for intravitreal injection.1 However, there are few reports 
of retinal function changes by electroretinography (ERG) after treatment with anti-
VEGF agents.2–4 The multifocal ERG allows the simultaneous derivation of 103 local 
ERG signals in a central visual field of about 50–60° diameter around the fovea. The 
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can be described in detail by this technique, which allows 
the functional mapping of the retina.5
The objective of the study was to determine the pattern 
of ERG change after an intravitreal ranibizumab injection, 
for patients with CNVM.
Materials and methods
The study was a prospective consecutive interventional 
study, under the approval of the Ethics Committee of 
Songklanagarind Hospital, Songkhla, Thailand. Patients were 
recruited from August 2007 to August 2008. The patients 
received a 0.5 mg intravitreal ranibizumab monotherapy 
for any type of CNVM confirmed by fundus fluorescein 
angiography (FFA). The method relies upon the results of the 
superiority of ranibizumab to photodynamic therapy (PDT) 
in all subgroups evaluated from the ANCHOR study.6
The informed consents of all subjects who participated 
in the study were obtained after the nature of the procedure 
and possible discomforts and risks had been fully explained. 
All patients received their first intravitreal injection in an 
operating room under an aseptic preparation technique within 
8 days after an angiographic study. Ranibizumab 0.5 mg 
(Lucentis®; Novartis Pharma AG, Basel, Switzerland) was 
injected intravitreally at 4.0 mm from the limbus in phakic 
eyes and at 3.5 mm in pseudophakic eyes. The patients 
were then instructed to take an antibiotic for 1 week and 
were scheduled for further postoperative visits at 2 weeks, 
1 month, and 3 months after the injection. Retreatment with 
an interval of a month was considered if the retinal condition 
was still active. Any post-operative complications such as 
prolonged inflammation, endophthalmitis and rapid cataract 
progression were recorded.
The primary outcome was a change in functional response 
of the signal amplitude or response density and the implicit 
time or P1 latency which were shown by 103 numeric values 
in a multifocal ERG (mfERG). The ERG (VERIS Science 
6.0.7 d15, EDI, Redwood City, CA, USA), as well as the 
patients, were prepared following the International Society 
for Clinical Electrophysiology of Vision (ISCEV) guidelines.7 
Each patient was light adapted for at least 15 minutes with 
room lights or at least two hours after an exposure to a bright 
light. The patients’ pupils were fully dilated before the test 
to maximize the retinal illumination. The mfERG response 
signals were classified into 3 zones for analysis of localized 
alteration (Figure 1). A central zone represented signals from 
7 central hexagons, a mid zone represented a middle ring of 
30 hexagons, and a peripheral zone represented 66 signals 
from hexagons in the peripheral macular area.
A structural change in central macular thickness was 
  considered as a secondary outcome. The thickness was 
measured by optical coherence tomography (OCT; Stra-
tus OCT III, v.4, Zeiss, Oberkochen, Germany). Fundus 
angiography was performed after informed consent was 
provided and the angiographic photos were captured by a 
Kowa VX-10i fundus camera (Kowa Co Ltd, Tokyo, Japan). 
Eyes that had been previously treated by laser photocoagula-
tion, photodynamic therapy, or intravitreal injection of any 
therapeutic agent were excluded from the study.
The program SPSS version 11.5 was used for data 
  processing. Statistical analyses included Student’s t-test for 
parametric data, Mann–Whitney U test for non-parametric 
data and Pearson’s correlation coefficient for a measure of 
association between two variables. A statistical difference was 
considered significant when the P-value was #0.05.
Results
The baseline demographic data are shown in Table 1. 
  Twenty-seven eyes from 26 consecutive patients were   initially 
enrolled in the study but 1 patient (1 eye) was excluded at 
the end of the study due to a protocol violation. The   average 
age of the remaining 25 patients was 66.5 ± 9.3 years. 
Seventeen patients were non-smokers, 3 were occasional 
smoking males, and 5 were prolonged (.1 year) ex-smoking 
males. The mean baseline best corrected visual acuity 
(VA) was 1.06 ± 0.51 logMAR (logarithm of   Minimum 
Angle of Resolution). Pre-operative FFA revealed 6 eyes 
(23.1%) with predominantly classic CNVM, 1 eye (3.8%) 
with minimally classic CNVM, and 19 eyes (73.1%) with 
Figure 1 A schematic illustration of topographical mferg map. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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occult CNVM. The greatest linear diameter (GLD) of the 
eyes with   predominantly classic CNVM varied from 878 to 
4,944 microns (mean 2,453.67 ± 1,454.81).
The studied eyes were divided into 2 groups post hoc; 
14 of 26 eyes (54%) in subgroup-A with initial VA . 1 
  logMAR (VA , 20/200) and 12 eyes (46%) in subgroup-B 
with initial VA # 1 logMAR (VA $ 20/200). The average 
age in subgroup-A was 69.9 years and in subgroup-B was 62.4 
years (P = 0.035). The preoperative mean macular thickness 
and intraocular pressure (IOP) were insignificantly different 
between subgroups (P = 0.451 and P = 0.754 respectively).
Twelve eyes received only one injection of intravitreal 
ranibizumab. Two eyes received their re-treatment once 
at a month apart. Eleven eyes received their re-treatment 
twice, in which case the second and the third ranibizumab 
injections were performed at one and two months after 
an initial   treatment. A patient who had bilateral active 
disease began her second eye treatment a month later after 
she had finished the third injection for the first eye. There 
was neither a serious postoperative complication nor a 
need for cataract surgery reported within 6 months after an 
intravitreal injection. One patient had chest discomfort and 
chest muscle twitching 6 hours after his second intravitreal 
injection that was relieved by medications. He refused a 
third injection.
The mean baseline IOP was 12.5 ± 2.5 mmHg. The mean 
IOPs at 2 weeks, 1 month, and 3 months after treatment were 
12.6, 12.3, and 10.9 mmHg, respectively. A statistically 
significant difference in IOP change was seen at the third 
month (P = 0.779, 0.922, and 0.011, respectively).
Primary outcome: functional change
The mean values of baseline amplitude or response   density 
(nV/deg2) and implicit time (mseconds) of all patients and 
of both subgroups are shown in Table 2. A   significant 
difference between subgroups appeared only in the 
amplitude of the mid zone. The overall mean implicit time 
of the central zone clearly demonstrated an improvement at 
3 months after   treatment when compared with the response 
at   baseline (P = 0.024) and at 1 month (P = 0.013). There 
was no   significant change in mean amplitude between   visits, 
compared to the baseline value. In a subgroup analysis 
(Figure 2), the significant change in subgroup-A was 
the amplitude in the mid zone at 1 month after treatment 
(P = 0.033). Only the mean implicit time of the peripheral 
zone in subgroup-B clearly showed an improvement at 
2 weeks after treatment (P = 0.028).
A subgroup comparison showed that the postoperative 
mean amplitude in the central and mid zones of subgroup-B 
Table 1 Baseline clinical characteristics of the patients
Characteristics
Mean age in years (range) (n = 25) 
no. (%) of female patients 
no. (%) of patients with systemic disease 
  no underlying disease 
  Diabetes mellitus 
  hypertension 
  Diabetes mellitus + hypertension 
  hypertension + other 
  Others 
no. (%) of right eye (n = 26) 
no. (%) of lens status 
  Phakic 
  Pseudophakic 
no. (%) of CnVM types 
  Predominantly classic 
  Minimally classic 
  Occult 
Mean duration of visual symptom  
in weeks (range) 
Mean VA in logMAr (range) 
Mean iOP in mmhg (range) 
Mean macular thickness in microns (range)
66.5 ± 9.3 (49–83) 
16 (64) 
 
9 (36) 
2 (8) 
8 (32) 
1 (4) 
2 (8) 
2 (8) 
12 (46.2) 
 
19 (73.1) 
7 (26.9) 
 
6 (23.1) 
1 (3.8) 
19 (73.1) 
19.3 ± 30.2 (0.5–120) 
 
1.06 ± 0.51 (0.3–1.7) 
12.5 ± 2.5 (7.2–18.0) 
389.7 ± 151.3 (177–724)
Abbreviations: CnVM, choroidal neovascularization membrane; VA, visual acuity; 
logMAr, logarithm of Minimum Angle of resolution; iOP, intraocular pressure; 
mmhg, millimeters of mercury.
Table 2 Baseline amplitude and implicit time
n Peripheral zone (66) Mid zone (30) Central zone (7)
Mean SD P-value Mean SD P-value Mean SD P-value
Amplitude
Overall 26 2.859 1.085 3.475 1.511 5.028 2.618
subgroup-A 14 2.570 1.160 0.198 2.827 1.313 0.024 4.586 3.104 0.143
subgroup-B 12 3.196 0.925 4.230 1.413 5.543 1.910
Implicit time
Overall 26 31.621 3.563 32.819 7.567 34.327 7.010
subgroup-A 14 31.907 3.119 0.700 34.656 4.350 0.328 35.060 5.286 0.797
subgroup-B 12 31.287 4.140 30.676 9.924 33.427 8.947
Notes: subgroup-A: initial VA , 20/200; subgroup-B: initial VA $ 20/200.
Abbreviation: sD, standard deviation. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
570
Bhurayanontachai et al
was better than that of subgroup-A at every follow-up visit 
(P , 0.02), whereas the mean implicit time had no significant 
difference between groups.
The mean postoperative VAs at 2 weeks, 1 month, and 
3 months were 1.03, 0.96, and 0.84 logMAR   respectively. The 
significant difference of VA change was found at 1 (P = 0.021) 
and 3 months (P = 0.034) after treatment. The correlation 
analysis also found a significant reversed association between 
changes in amplitude and logMAR VA in the central and mid 
zones from 2 weeks onwards (P , 0.002), however, there 
was no correlation between the changes in implicit time and 
logMAR VA.
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Figure 2 A–C) A change from baseline in nanovolts/deg2 of the mean amplitude over time in the central, mid, and peripheral zones. D–F) A change from baseline in 
milliseconds of the mean implicit time over time in the central, mid, and peripheral zones. The vertical line = 1 standard error. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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secondary outcome: structural change
The mean macular thicknesses were 389.7 ± 151.3 microns 
preoperatively, 290.0 microns at 1 month (P < 0.001) and 
264.4 microns at 3 months (P = 0.003) postoperatively. 
Postoperative changes in macular thickness showed 
no   significant difference among subgroups and had no 
correlation with either amplitude or implicit time.
Discussion
The present pilot study of an electrophysiologic response 
after an intravitreal ranibizumab injection included all 
ranges of initial VA in order to compare the pattern of 
electrophysiologic changes regardless of the visual outcome. 
Nevertheless, we performed a subgroup analysis to test the 
effect of disease severity, indicated by the level of vision, 
upon the response of mfERG.
The overall results showed a prominent improvement 
in the implicit time rather than the amplitude at 3 months 
after treatment, although there were a few significant 
  postoperative differences within each subgroup. The 
patients in subgroup-B who had a better baseline VA were 
also significantly younger than the patients in subgroup-A 
(P = 0.035). The mean amplitude of subgroup-B was 
also better than that of subgroup-A on every visit, while 
the mean implicit time was not significantly different. 
This markedly showed a moderate to high statistical 
correlation of the signal amplitude with a patient’s VA 
(P , 0.02). Thus, age may have an effect on an amplitude 
difference between groups, but from the result of this 
study it has no effect on the implicit time. Moreover, 
the improvement in the implicit time after the treatment 
indicates that the potency of functional recovery does not 
depend on age.
A significant reversed association between the ampli-
tude and logMAR of VA indicates that the higher the rising 
amplitudes, the better the vision gains. This difference also 
shows that a patient’s VA has a concordance with the signal 
amplitude or response density of mfERG, not the implicit 
time. However, the implicit time indicates an early functional 
improvement after the treatment. Gerth et al8 reported that 
the implicit times were found to be more sensitive in detect-
ing abnormal retinal responses compared with the amplitude 
or response density. Thus, in the recovering retinal area 
a decrease in the implicit time may occur earlier than an 
increase in the amplitude.
After treatment, the OCT revealed a decrease in macular 
thickness by a strong significance (P , 0.003) while the 
mean VA had a lesser degree of significant improvement 
at the same time (P , 0.034). Our study shows similar 
results as in the bevacizumab and ranibizumab treatments 
from the   previous reports.2–4 Therefore, anti-VEGF therapy 
can structurally reduce the macular edema, but may not 
fully recover the neuroretinal function. The next question 
is whether or not we can accelerate the improvement of 
vision. A method of vision restoration therapy (VRT)9 may 
be interesting because the early improvement area is mostly 
confined to the central and mid zones of the macula.
The limitation of this study is a lack of OCT data in 
some patients during an unfortunate period of machine 
malfunction. We not only recommend a future study with 
a longer follow-up period and a larger population, but 
also encourage the possibility of a careful visual reha-
bilitation trial of the watershed area by vision restoration 
therapy in the patients undergoing intravitreal ranibizumab 
treatments.
Conclusion
The mean implicit time of the central zone improved 
significantly at 3 months after treatment, whereas the mean 
amplitude had no significant change. There was a   correlation 
between baseline VA and the amplitude of mfERG, but not 
the implicit time. The OCT also showed a decrease in macular 
thickness along with an improvement of VA after   treatment. 
Continuous treatment with intravitreal ranibizumab 
monotherapy is required to evaluate the   long-term results.
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